Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 February 2003:
Vol. 299. no. 5611, pp. 1410 - 1413
DOI: 10.1126/science.1081578
Prev | Table of Contents

Reports

Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban

Joachim P. Schmitt,1* Mitsuhiro Kamisago,12* Michio Asahi,3* Guo Hua Li,1 Ferhaan Ahmad,1 Ulrike Mende,2 Evangelia G. Kranias,4 David H. MacLennan,3 J. G. Seidman,1 Christine E. Seidman12dagger

Molecular etiologies of heart failure, an emerging cardiovascular epidemic affecting 4.7 million Americans and costing 17.8 billion health-care dollars annually, remain poorly understood. Here we report that an inherited human dilated cardiomyopathy with refractory congestive heart failure is caused by a dominant Arg rightarrow  Cys missense mutation at residue 9 (R9C) in phospholamban (PLN), a transmembrane phosphoprotein that inhibits the cardiac sarcoplasmic reticular Ca2+-adenosine triphosphatase (SERCA2a) pump. Transgenic PLNR9C mice recapitulated human heart failure with premature death. Cellular and biochemical studies revealed that, unlike wild-type PLN, PLNR9C did not directly inhibit SERCA2a. Rather, PLNR9C trapped protein kinase A (PKA), which blocked PKA-mediated phosphorylation of wild-type PLN and in turn delayed decay of calcium transients in myocytes. These results indicate that myocellular calcium dysregulation can initiate human heart failure--a finding that may lead to therapeutic opportunities.

1 Department of Genetics, Harvard Medical School and Howard Hughes Medical Institute, 200 Longwood Avenue, Boston, MA 02115, USA.
2 Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
3 Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario M5G1L6, Canada.
4 Department of Pharmacology and Cell Biophysics, University of Cincinnati, Cincinnati, OH 45267, USA.
*   These authors contributed equally to this work.

dagger    To whom correspondence should be addressed. E-mail: cseidman{at}rascal.med.harvard.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump.
I. Vandecaetsbeek, M. Trekels, M. De Maeyer, H. Ceulemans, E. Lescrinier, L. Raeymaekers, F. Wuytack, and P. Vangheluwe (2009)
PNAS 106, 18533-18538
   Abstract »    Full Text »    PDF »
Calcium Pumps in Health and Disease.
M. Brini and E. Carafoli (2009)
Physiol Rev 89, 1341-1378
   Abstract »    Full Text »    PDF »
Mutations in ribonucleic Acid binding protein gene cause familial dilated cardiomyopathy..
K. M. Brauch, M. L. Karst, K. J. Herron, M. de Andrade, P. A. Pellikka, R. J. Rodeheffer, V. V. Michels, and T. M. Olson (2009)
J. Am. Coll. Cardiol. 54, 930-941
   Abstract »    Full Text »    PDF »
Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approach.
N. J. Traaseth, L. Shi, R. Verardi, D. G. Mullen, G. Barany, and G. Veglia (2009)
PNAS 106, 10165-10170
   Abstract »    Full Text »    PDF »
Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy.
L. Suckau, H. Fechner, E. Chemaly, S. Krohn, L. Hadri, J. Kockskamper, D. Westermann, E. Bisping, H. Ly, X. Wang, et al. (2009)
Circulation 119, 1241-1252
   Abstract »    Full Text »    PDF »
Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2+-ATPase Inhibition.
J. P. Schmitt, F. Ahmad, K. Lorenz, L. Hein, S. Schulz, M. Asahi, D. H. MacLennan, C. E. Seidman, J.G. Seidman, and M. J. Lohse (2009)
Circulation 119, 436-444
   Abstract »    Full Text »    PDF »
The Anti-apoptotic Protein HAX-1 Interacts with SERCA2 and Regulates Its Protein Levels to Promote Cell Survival.
E. Vafiadaki, D. A. Arvanitis, S. N. Pagakis, V. Papalouka, D. Sanoudou, A. Kontrogianni-Konstantopoulos, and E. G. Kranias (2009)
Mol. Biol. Cell 20, 306-318
   Abstract »    Full Text »    PDF »
CHAPTER 18 Myocardial Disease.
O. M. Hess, W. McKenna, and H.-P. Schultheiss (2009)
ESC Textbook of Cardiovascular Medicine 2, med-9780199566990-chapter
   Abstract »    Full Text »    PDF »
Phosphorylation of the cAMP-dependent Protein Kinase (PKA) Regulatory Subunit Modulates PKA-AKAP Interaction, Substrate Phosphorylation, and Calcium Signaling in Cardiac Cells.
S. Manni, J. H. Mauban, C. W. Ward, and M. Bond (2008)
J. Biol. Chem. 283, 24145-24154
   Abstract »    Full Text »    PDF »
Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling.
X. Loyer, A. M. Gomez, P. Milliez, M. Fernandez-Velasco, P. Vangheluwe, L. Vinet, D. Charue, E. Vaudin, W. Zhang, Y. Sainte-Marie, et al. (2008)
Circulation 117, 3187-3198
   Abstract »    Full Text »    PDF »
Gene Therapy in Heart Failure.
L. E. Vinge, P. W. Raake, and W. J. Koch (2008)
Circ. Res. 102, 1458-1470
   Abstract »    Full Text »    PDF »
A Missense Mutation in the CHRM2 Gene Is Associated With Familial Dilated Cardiomyopathy.
L. Zhang, A. Hu, H. Yuan, L. Cui, G. Miao, X. Yang, L. Wang, J. Liu, X. Liu, S. Wang, et al. (2008)
Circ. Res. 102, 1426-1432
   Abstract »    Full Text »    PDF »
Comparative Proteomics Profiling of a Phospholamban Mutant Mouse Model of Dilated Cardiomyopathy Reveals Progressive Intracellular Stress Responses.
A. O. Gramolini, T. Kislinger, R. Alikhani-Koopaei, V. Fong, N. J. Thompson, R. Isserlin, P. Sharma, G. Y. Oudit, M. G. Trivieri, A. Fagan, et al. (2008)
Mol. Cell. Proteomics 7, 519-533
   Abstract »    Full Text »    PDF »
Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure.
Y. Ikeda, M. Hoshijima, and K. R. Chien (2008)
Physiology 23, 6-16
   Abstract »    Full Text »    PDF »
Controlling the Inhibition of the Sarcoplasmic Ca2+-ATPase by Tuning Phospholamban Structural Dynamics.
K. N. Ha, N. J. Traaseth, R. Verardi, J. Zamoon, A. Cembran, C. B. Karim, D. D. Thomas, and G. Veglia (2007)
J. Biol. Chem. 282, 37205-37214
   Abstract »    Full Text »    PDF »
Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and {alpha}-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments.
P. Robinson, P. J. Griffiths, H. Watkins, and C. S. Redwood (2007)
Circ. Res. 101, 1266-1273
   Abstract »    Full Text »    PDF »
Inherited Arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report About the Diagnosis, Phenotyping, Molecular Mechanisms, and Therapeutic Approaches for Primary Cardiomyopathies of Gene Mutations Affecting Ion Channel Function.
S. E. Lehnart, M. J. Ackerman, D. W. Benson Jr, R. Brugada, C. E. Clancy, J. K. Donahue, A. L. George Jr, A. O. Grant, S. C. Groft, C. T. January, et al. (2007)
Circulation 116, 2325-2345
   Abstract »    Full Text »    PDF »
Cardiac Transgenic and Gene Transfer Strategies Converge to Support an Important Role for Troponin I in Regulating Relaxation in Cardiac Myocytes.
S.-i. Yasuda, P. Coutu, S. Sadayappan, J. Robbins, and J. M. Metzger (2007)
Circ. Res. 101, 377-386
   Abstract »    Full Text »    PDF »
Percutaneous Cardiac Recirculation-Mediated Gene Transfer of an Inhibitory Phospholamban Peptide Reverses Advanced Heart Failure in Large Animals.
D. M. Kaye, A. Preovolos, T. Marshall, M. Byrne, M. Hoshijima, R. Hajjar, J. A. Mariani, S. Pepe, K. R. Chien, and J. M. Power (2007)
J. Am. Coll. Cardiol. 50, 253-260
   Abstract »    Full Text »    PDF »
Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse {alpha}-cardiac myosin in the laser trap assay.
E. P. Debold, J. P. Schmitt, J. B. Patlak, S. E. Beck, J. R. Moore, J. G. Seidman, C. Seidman, and D. M. Warshaw (2007)
Am J Physiol Heart Circ Physiol 293, H284-H291
   Abstract »    Full Text »    PDF »
Phospholamban and sarcolipin are maintained in the endoplasmic reticulum by retrieval from the ER-Golgi intermediate compartment.
J. Butler, A. G. Lee, D. I. Wilson, C. Spalluto, N. A. Hanley, and J. M. East (2007)
Cardiovasc Res 74, 114-123
   Abstract »    Full Text »    PDF »
Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure.
A. P. Saliaris, L. C. Amado, K. M. Minhas, K. H. Schuleri, S. Lehrke, M. St. John, T. Fitton, C. Barreiro, C. Berry, M. Zheng, et al. (2007)
Am J Physiol Heart Circ Physiol 292, H1328-H1335
   Abstract »    Full Text »    PDF »
Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation.
M. Medin, M. Hermida-Prieto, L. Monserrat, R. Laredo, J. C. Rodriguez-Rey, X. Fernandez, and A. Castro-Beiras (2007)
Eur J Heart Fail 9, 37-43
   Abstract »    Full Text »    PDF »
Familial inflammatory dilated cardiomyopathy.
I. Portig, A. Wilke, M. Freyland, M.-J. Wolf, A. Richter, V. Ruppert, S. Pankuweit, and B. Maisch (2006)
Eur J Heart Fail 8, 816-825
   Abstract »    Full Text »    PDF »
Candidate Gene Expression Analysis of Toxin-Induced Dilated Cardiomyopathy in the Turkey (Meleagris gallopavo).
K.-C. Lin, K. Gyenai, R. L. Pyle, T. Geng, J. Xu, and E. J. Smith (2006)
Poult. Sci. 85, 2216-2221
   Abstract »    Full Text »    PDF »
Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo.
Y. Yang, W.-Z. Zhu, M.-l. Joiner, R. Zhang, C. V. Oddis, Y. Hou, J. Yang, E. E. Price, L. Gleaves, M. Eren, et al. (2006)
Am J Physiol Heart Circ Physiol 291, H3065-H3075
   Abstract »    Full Text »    PDF »
The Genetic Bases of Cardiomyopathies.
P. Richard, E. Villard, P. Charron, and R. Isnard (2006)
J. Am. Coll. Cardiol. 48, A79-A89
   Abstract »    Full Text »    PDF »
Transcriptional response to persistent {beta}2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility.
D. W. McGraw, K. M. Fogel, S. Kong, A. A. Litonjua, E. G. Kranias, B. J. Aronow, and S. B. Liggett (2006)
Physiol Genomics 27, 171-177
   Abstract »    Full Text »    PDF »
Redefining Heart Failure: The Utility of Genomics.
M. P. Donahue, D. A. Marchuk, and H. A. Rockman (2006)
J. Am. Coll. Cardiol. 48, 1289-1298
   Abstract »    Full Text »    PDF »
Phospholamban R14 Deletion Results in Late-Onset, Mild, Hereditary Dilated Cardiomyopathy.
M. M. DeWitt, H. M. MacLeod, B. Soliven, and E. M. McNally (2006)
J. Am. Coll. Cardiol. 48, 1396-1398
   Abstract »    Full Text »    PDF »
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.
J. P. Schmitt, E. P. Debold, F. Ahmad, A. Armstrong, A. Frederico, D. A. Conner, U. Mende, M. J. Lohse, D. Warshaw, C. E. Seidman, et al. (2006)
PNAS 103, 14525-14530
   Abstract »    Full Text »    PDF »
KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension.
G. C. Kane, A. Behfar, R. B. Dyer, D. F. O'Cochlain, X.-K. Liu, D. M. Hodgson, S. Reyes, T. Miki, S. Seino, and A. Terzic (2006)
Hum. Mol. Genet. 15, 2285-2297
   Abstract »    Full Text »    PDF »
Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy.
G. D. Mills, H. Kubo, D. M. Harris, R. M. Berretta, V. Piacentino III, and S. R. Houser (2006)
Am J Physiol Heart Circ Physiol 291, H61-H70
   Abstract »    Full Text »    PDF »
The Presence of Lys27 Instead of Asn27 in Human Phospholamban Promotes Sarcoplasmic Reticulum Ca2+-ATPase Superinhibition and Cardiac Remodeling.
W. Zhao, Q. Yuan, J. Qian, J. R. Waggoner, A. Pathak, G. Chu, B. Mitton, X. Sun, J. Jin, J. C. Braz, et al. (2006)
Circulation 113, 995-1004
   Abstract »    Full Text »    PDF »
Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation.
A. O. Gramolini, M. G. Trivieri, G. Y. Oudit, T. Kislinger, W. Li, M. M. Patel, A. Emili, E. G. Kranias, P. H. Backx, and D. H. MacLennan (2006)
PNAS 103, 2446-2451
   Abstract »    Full Text »    PDF »
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.
K. Haghighi, F. Kolokathis, A. O. Gramolini, J. R. Waggoner, L. Pater, R. A. Lynch, G.-C. Fan, D. Tsiapras, R. R. Parekh, G. W. Dorn II, et al. (2006)
PNAS 103, 1388-1393
   Abstract »    Full Text »    PDF »
Microdomains of Intracellular Ca2+: Molecular Determinants and Functional Consequences.
R. Rizzuto and T. Pozzan (2006)
Physiol Rev 86, 369-408
   Abstract »    Full Text »    PDF »
Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure.
T. Dieterle, M. Meyer, Y. Gu, D. D. Belke, E. Swanson, M. Iwatate, J. Hollander, K. L. Peterson, J. Ross Jr., and W. H. Dillmann (2005)
Cardiovasc Res 67, 678-688
   Abstract »    Full Text »    PDF »
Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice.
L. C. Mounkes, S. V. Kozlov, J. N. Rottman, and C. L. Stewart (2005)
Hum. Mol. Genet. 14, 2167-2180
   Abstract »    Full Text »    PDF »
Does load-induced ventricular hypertrophy progress to systolic heart failure?.
K. Berenji, M. H. Drazner, B. A. Rothermel, and J. A. Hill (2005)
Am J Physiol Heart Circ Physiol 289, H8-H16
   Abstract »    Full Text »    PDF »
Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies.
D. Sanoudou, E. Vafiadaki, D. A. Arvanitis, E. Kranias, and A. Kontrogianni-Konstantopoulos (2005)
Physiol Genomics 21, 131-143
   Abstract »    Full Text »    PDF »
Clinical and genetic issues in familial dilated cardiomyopathy.
E. L. Burkett and R. E. Hershberger (2005)
J. Am. Coll. Cardiol. 45, 969-981
   Abstract »    Full Text »    PDF »
Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene.
E. Villard, L. Duboscq-Bidot, P. Charron, A. Benaiche, V. Conraads, N. Sylvius, and M. Komajda (2005)
Eur. Heart J. 26, 794-803
   Abstract »    Full Text »    PDF »
Mapping the interaction surface of a membrane protein: Unveiling the conformational switch of phospholamban in calcium pump regulation.
J. Zamoon, F. Nitu, C. Karim, D. D. Thomas, and G. Veglia (2005)
PNAS 102, 4747-4752
   Abstract »    Full Text »    PDF »
Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies.
P. Coutu and J. M. Metzger (2005)
Am J Physiol Heart Circ Physiol 288, H601-H612
   Abstract »    Full Text »    PDF »
Sodium Channel Mutations and Susceptibility to Heart Failure and Atrial Fibrillation.
T. M. Olson, V. V. Michels, J. D. Ballew, S. P. Reyna, M. L. Karst, K. J. Herron, S. C. Horton, R. J. Rodeheffer, and J. L. Anderson (2005)
JAMA 293, 447-454
   Abstract »    Full Text »    PDF »
Two novel mutations in the {beta}-myosin heavy chain gene associated with dilated cardiomyopathy.
S. Karkkainen, T. Helio, P. Jaaskelainen, R. Miettinen, P. Tuomainen, K. Ylitalo, M. Kaartinen, E. Reissell, L. Toivonen, M. S. Nieminen, et al. (2004)
Eur J Heart Fail 6, 861-868
   Abstract »    Full Text »    PDF »
Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy.
T. Tang, M. H. Gao, D. M. Roth, T. Guo, and H. K. Hammond (2004)
Am J Physiol Heart Circ Physiol 287, H1906-H1912
   Abstract »    Full Text »    PDF »
Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice.
M. Asahi, K. Otsu, H. Nakayama, S. Hikoso, T. Takeda, A. O. Gramolini, M. G. Trivieri, G. Y. Oudit, T. Morita, Y. Kusakari, et al. (2004)
PNAS 101, 9199-9204
   Abstract »    Full Text »    PDF »
A novel mutation, Ser143Pro, in the lamin A/C gene is common in finnish patients with familial dilated cardiomyopathy.
S. Karkkainen, T. Helio, R. Miettinen, P. Tuomainen, P. Peltola, J. Rummukainen, K. Ylitalo, M. Kaartinen, J. Kuusisto, L. Toivonen, et al. (2004)
Eur. Heart J. 25, 885-893
   Abstract »    Full Text »    PDF »
Return of calcium: Manipulating intracellular calcium to prevent cardiac pathologies.
Y. Wang and J. I. Goldhaber (2004)
PNAS 101, 5697-5698
   Full Text »    PDF »
Hypertrophy of the Heart: A New Therapeutic Target?.
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill (2004)
Circulation 109, 1580-1589
   Abstract »    Full Text »    PDF »
Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6).
S A Mohiddin, Z M Ahmed, A J Griffith, D Tripodi, T B Friedman, L Fananapazir, and R J Morell (2004)
J. Med. Genet. 41, 309-314
   Full Text »    PDF »
Altered Calcium Handling Is Critically Involved in the Cardiotoxic Effects of Chronic {beta}-Adrenergic Stimulation.
S. Engelhardt, L. Hein, V. Dyachenkow, E. G. Kranias, G. Isenberg, and M. J. Lohse (2004)
Circulation 109, 1154-1160
   Abstract »    Full Text »    PDF »
A Cypher/ZASP Mutation Associated with Dilated Cardiomyopathy Alters the Binding Affinity to Protein Kinase C.
T. Arimura, T. Hayashi, H. Terada, S.-Y. Lee, Q. Zhou, M. Takahashi, K. Ueda, T. Nouchi, S. Hohda, M. Shibutani, et al. (2004)
J. Biol. Chem. 279, 6746-6752
   Abstract »    Full Text »    PDF »
Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men.
G. W. Dorn II and J. D. Molkentin (2004)
Circulation 109, 150-158
   Full Text »    PDF »
Cardiomyocyte Calcium and Calcium/Calmodulin-dependent Protein Kinase II: Friends or Foes?.
T. Zhang, S. Miyamoto, and J. H. Brown (2004)
Recent Prog. Horm. Res. 59, 141-168
   Abstract »    Full Text »
Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction.
M. Vatta, B. Mohapatra, S. Jimenez, X. Sanchez, G. Faulkner, Z. Perles, G. Sinagra, J.-H. Lin, T. M. Vu, Q. Zhou, et al. (2003)
J. Am. Coll. Cardiol. 42, 2014-2027
   Abstract »    Full Text »    PDF »
Modeling {beta}-Adrenergic Control of Cardiac Myocyte Contractility in Silico.
J. J. Saucerman, L. L. Brunton, A. P. Michailova, and A. D. McCulloch (2003)
J. Biol. Chem. 278, 47997-48003
   Abstract »    Full Text »    PDF »
What Is the Role of {beta}-Adrenergic Signaling in Heart Failure?.
M. J. Lohse, S. Engelhardt, and T. Eschenhagen (2003)
Circ. Res. 93, 896-906
   Abstract »    Full Text »    PDF »
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations.
P Sebillon, C Bouchier, L D Bidot, G Bonne, K Ahamed, P Charron, V Drouin-Garraud, A Millaire, G Desrumeaux, A Benaiche, et al. (2003)
J. Med. Genet. 40, 560-567
   Abstract »    Full Text »    PDF »
Calcium and the Failing Heart: Phospholamban, Good Guy or Bad Guy?.
R. H. G. Schwinger and K. F. Frank (2003)
Sci. STKE 2003, pe15
   Abstract »    Full Text »    PDF »
Pediatric Cardiomyopathy -- A Long Way to Go.
A. Strauss and J. E. Lock (2003)
N. Engl. J. Med. 348, 1703-1705
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)